There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on POINT Biopharma Global (PNT – Research Report), Horizon Therapeutics (HZNP – Research Report) and ImmunoGen (IMGN – Research Report) with bullish sentiments. POINT Biopharma Global (PNT) Brookline Capital Markets analyst Kemp Dolliver reiterated a Buy rating on POINT Biopharma Global today and set a price target of $23.00. The company's shares closed last Friday at $8.21. According to TipRanks.
https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-144?utm_source=advfn.com&utm_medium=referral
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more ImmunoGen Charts.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more ImmunoGen Charts.